ondasdechoque.org
PT-BR

Individualized radial waves for calcific shoulder pain · Single-group study · 2017

Does calcific shoulder pain ease with tailored radial shockwave?

In this study, people had radial shockwave once a week, tailored to them, about 7 sessions on average. Shoulder pain fell from about 7 out of 10 to under 3 at one month and under 1 at one year. Of 76 treated shoulders, 71 needed no further treatment.

Improved over time
people followed up (76 shoulders)
64
sessions on average (4 to 11), one a week
7
year of follow-up
1

Good to know: No comparison group; followed for one year. Side effects were minor: mild skin irritation or brief discomfort.

Malliaropoulos N, Thompson D, Meke M, et al. BMC Musculoskelet Disord, 2017 · Read the paper ↗

How this study worked

StartFollow-up67 people
One group was followed over time, without a comparison group. Each dot is one person.

What happened

Shoulder pain over a year

0–10 pain scale · start, then 1, 3 and 12 months

Radial shockwave

Pain fell from about 7 out of 10 at the start to under 3 at one month, under 2 at three months and under 1 at one year.
Show the numbers
GroupStart1 month3 months1 year
Radial shockwave6.72.61.70.8

The treatment

Radial shockwave

Radial, once a week for 7 weeks

Radial wavesSpread out from the skin; strongest near the surface
Sessions
7, one a week
Pulses
2,175 per session · average; the number of sessions (4 to 11) and settings were adjusted to each person
Strength
1.7bar average · 5 per second
Numbing
Not mentioned
Device
Masterpuls MP200
Everyone also got
Advice to avoid anti-inflammatory painkillers

Compared with: No comparison group

Settings are what each study used, not a prescription.

Who took part

67 adults (average age about 45) with calcium deposits in a shoulder tendon; 64 people (76 shoulders) completed follow-up.

hollow squares: no final score

Radial shockwave64 of 67 measured
64 of 67 people (96%) had a final score.

Side effects

Five people had minor side effects: three had mild skin irritation and two had discomfort lasting up to two days. No one stopped because of side effects.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

67 people with 79 shoulders entered; three withdrew for financial/time reasons, leaving 64 people and 76 shoulders. Mean age 44.7±8.1 years; 25 men,39 women. Acute severe calcific pain, cuff rupture, previous surgery, recent steroid injection and previous ESWT were excluded.

Radial ESWT cohort67enrolled

67 enrolled people/79 shoulders; 64 analyzed people/76 shoulders. Outcome n refers to shoulders, not people.

Shoulder pain4 reported outcomes
01
End of treatment

Shoulder pain

VAS points

BaselineFollow-up
Radial ESWT cohort
3.2
010 points
means
GroupnBaselineFollow-up
Radial ESWT cohort—6.7 (SD 1.1)3.2 (SD 0.8)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

76 shoulders in 64 people; paired shoulders are not independent participants. Descriptive uncontrolled change.

02
One month

Shoulder pain

VAS points

BaselineFollow-up
Radial ESWT cohort
2.6
010 points
means
GroupnBaselineFollow-up
Radial ESWT cohort—6.7 (SD 1.1)2.6 (SD 0.9)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

76 shoulders in 64 people; paired shoulders are not independent participants. Descriptive uncontrolled change.

03
Three months

Shoulder pain

VAS points

BaselineFollow-up
Radial ESWT cohort
1.7
010 points
means
GroupnBaselineFollow-up
Radial ESWT cohort—6.7 (SD 1.1)1.7 (SD 1)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

76 shoulders in 64 people; paired shoulders are not independent participants. Descriptive uncontrolled change.

04
One year

Shoulder pain

VAS points

BaselineFollow-up
Radial ESWT cohort
0.8
010 points
means
GroupnBaselineFollow-up
Radial ESWT cohort—6.7 (SD 1.1)0.8 (SD 1)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

76 shoulders in 64 people; paired shoulders are not independent participants. Descriptive uncontrolled change.

Success and recurrence1 reported outcome
05
As reported in the article

Success and recurrence

Qualitative finding

VAS fell from 6.7±1.1 to 3.2±0.8,2.6±0.9,1.7±1.0 and 0.8±1.0. Figure 2 gives success 12%,51%,82%,92% at corresponding visits. Recurrence 7%, with 71/76 shoulders not requiring further treatment. Longer pretreatment duration correlated weakly with worse later pain; it did not correlate with session count (r=.080, p=.494).

Analysis details and source

Qualitative extraction preserves the source scope.

Minor adverse events1 reported outcome
06
As reported in the article

Minor adverse events

Qualitative finding

Five patients had minor events: three mild skin irritation and two discomfort lasting up to two days. No adverse-event withdrawals; no long-term analgesia reported.

Analysis details and source

Qualitative extraction preserves the source scope.

How treatment was delivered
Individualized regimen

Masterpuls MP200 radial waves after ultrasound localization and coupling gel, weekly. Mean seven±1.5 sessions (reported range 4–11), pressure 1.7±0.2 bar, frequency 5±0.3 Hz, 2175±266 pulses. Settings followed tolerance; minimum three sessions planned; stop at VAS≤2 or marked improvement. NSAIDs discouraged.

HARMS & TOLERABILITY

Five patients had minor events: three mild skin irritation and two discomfort lasting up to two days. No adverse-event withdrawals; no long-term analgesia reported.

LIMITS OF THE ANALYSIS

No control, retrospective selection, response-driven treatment duration, bilateral shoulders without clearly described clustering adjustment, no standardized function score or post-treatment calcification resolution assessment. Table 3 lists 74 shoulders at session 4 although reported minimum is 4, a source inconsistency. Storz paid publication costs; Lohrer declared research support and paid speaking.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • No control, retrospective selection, response-driven treatment duration, bilateral shoulders without clearly described clustering adjustment, no standardized function score or post-treatment calcification resolution assessment. Table 3 lists 74 shoulders at session 4 although reported minimum is 4, a source inconsistency. Storz paid publication costs; Lohrer declared research support and paid speaking.
Research review

Source-linked critical reading

uncontrolled clinical

Reading depthMaterial consulted
Technical source record

Complete local PDF text read, including all article body sections, tables, figure captions, discussion, disclosures and references. The article lists no supplementary material.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Retrospective single-centre uncontrolled cohort, Greece, 2006–2013. There was no randomization or comparator and the treatment stopping rule depended on symptom improvement.

Participants and setting

67 people with 79 shoulders entered; three withdrew for financial/time reasons, leaving 64 people and 76 shoulders. Mean age 44.7±8.1 years; 25 men,39 women. Acute severe calcific pain, cuff rupture, previous surgery, recent steroid injection and previous ESWT were excluded.

Treatment

Masterpuls MP200 radial waves after ultrasound localization and coupling gel, weekly. Mean seven±1.5 sessions (reported range 4–11), pressure 1.7±0.2 bar, frequency 5±0.3 Hz, 2175±266 pulses. Settings followed tolerance; minimum three sessions planned; stop at VAS≤2 or marked improvement. NSAIDs discouraged.

Comparison

No control arm; comparisons with published fixed protocols are indirect and cannot show individualized treatment superiority.

Outcomes and timing

VAS 0–10 including night pain at treatment completion,1,3 and 12 months. Success generally defined as >60% pain reduction; abstract uses ≥60%. Recurrence meant additional treatment or VAS≥2 at one year. Outcomes predominantly use shoulders rather than independent people.

What the results show

VAS fell from 6.7±1.1 to 3.2±0.8,2.6±0.9,1.7±1.0 and 0.8±1.0. Figure 2 gives success 12%,51%,82%,92% at corresponding visits. Recurrence 7%, with 71/76 shoulders not requiring further treatment. Longer pretreatment duration correlated weakly with worse later pain; it did not correlate with session count (r=.080, p=.494).

Harms

Five patients had minor events: three mild skin irritation and two discomfort lasting up to two days. No adverse-event withdrawals; no long-term analgesia reported.

Limits and disclosures

No control, retrospective selection, response-driven treatment duration, bilateral shoulders without clearly described clustering adjustment, no standardized function score or post-treatment calcification resolution assessment. Table 3 lists 74 shoulders at session 4 although reported minimum is 4, a source inconsistency. Storz paid publication costs; Lohrer declared research support and paid speaking.

Application to care

This describes feasibility and symptom trajectories in selected nonacute patients. Natural resorption, regression to the mean and care effects remain plausible explanations for improvement.

What remains to be tested

Compare individualized and fixed radial protocols with sham or usual care, account for paired shoulders, and measure function, imaging, tolerance and cost prospectively.

THE ORIGINAL SOURCE

Read the original article.

Individualised radial extracorporeal shock wave therapy (rESWT) for symptomatic calcific shoulder tendinopathy: a retrospective clinical study

Malliaropoulos N, Thompson D, Meke M, Pyne D, Alaseirlis D, Atkinson H, Korakakis V, Lohrer H. · BMC Musculoskelet Disord · 2017

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →